<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05028855</url>
  </required_header>
  <id_info>
    <org_study_id>CASCAS</org_study_id>
    <nct_id>NCT05028855</nct_id>
  </id_info>
  <brief_title>Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis</brief_title>
  <acronym>CASCAS</acronym>
  <official_title>Cerebral Autoregulation in Patients With Symptomatic Cerebral Atherosclerotic Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yi Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shenzhen Second People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Jiao Tong University Affiliated Sixth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of University of South China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eighth Affiliated Hospital, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Hebei North University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Yanbian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this multi-center prospective observational study within a cohort of symptomatic cerebral&#xD;
      atherosclerotic stenosis (sCAS) patients, 850 subjects were planed to be enrolled to explore&#xD;
      the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the&#xD;
      threshold values of CA parameter for predicting stroke recurrence associated with particular&#xD;
      stenosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ischemic stroke is a tremendous public health burden that seriously endangers the health of&#xD;
      Chinese population symptomatic cerebral atherosclerotic stenosis (sCAS) is responsible for&#xD;
      about 33-50% of ischemic stroke in China and highly associated with the risk of stroke&#xD;
      recurrence.&#xD;
&#xD;
      Cerebral autoregulation (CA) is the main protective mechanism that modulates cerebral blood&#xD;
      flow to satisfy regional cerebral perfusion demands despite of variations in arterial blood&#xD;
      pressure (ABP). Thus, CA supposed to be particularly considered when choosing individual&#xD;
      therapeutic strategy in sCAS patients. In clinical practice, applying transcranial Doppler&#xD;
      combined with servo-controlled plethysmograph assessing CA has been proved a feasible method&#xD;
      in cerebral atherosclerotic stenosis patients. Especially in those severe stenosis patients,&#xD;
      CA is probably compromised in varying degrees, whereas whether and to what extent CA&#xD;
      parameters have the capability to predict stroke recurrence has not been illustrated.&#xD;
&#xD;
      Thus, the aim of the study was to assess CA after acute ischemic stroke or transient ischemic&#xD;
      attack within 2 years follow-up to explore the relationship between CA and stroke recurrence&#xD;
      and determine the threshold values of CA parameter to predict stroke recurrence. CA&#xD;
      measurement will be performed at 0-3 and 10-30 days after ischemic cerebrovascular events.&#xD;
      Clinical information, neuroimaging data, biochemical examinations and follow-up information&#xD;
      will be collected and recorded in case report form (CRF) once signing of informed consent.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 14, 2017</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 24, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Stroke recurrence rate</measure>
    <time_frame>two years</time_frame>
    <description>Ischemic cerebrovascular recurrence (TIA or ischemic stroke) within cerebral stenotic artery supplying area diagnosed by symptoms and imaging examinations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The index of cerebral autoregulation</measure>
    <time_frame>within 30 days ischemic cerebrovascular events onset</time_frame>
    <description>Phase difference, gain and coherence of symptomatic cerebral atherosclerotic stenosis patients within 30 days ischemic cerebrovascular events onset.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic cerebrovascular recurrence rate</measure>
    <time_frame>two years</time_frame>
    <description>All ischemic cerebrovascular recurrence (TIA or ischemic stroke) within two years follow-up diagnosed by symptoms and imaging examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The first onset time of composite endpoint events within 2 years</measure>
    <time_frame>two years follow-up</time_frame>
    <description>The composite endpoint events include fatal and nonfatal stroke (ischemic or hemorrhagic stroke), fatal and nonfatal myocardial infarction, transient ischemic attack (TIA) diagnosed by symptoms and imaging examinations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mRS and Barthel score</measure>
    <time_frame>two years</time_frame>
    <description>The changes of mRS and Barthel score within 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The first onset time of each individual part of composite endpoint events within 2 years</measure>
    <time_frame>two years follow-up</time_frame>
    <description>The first onset time of each individual part of composite endpoint events within 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the NIHSS score</measure>
    <time_frame>within 1 month</time_frame>
    <description>The changes of NIHSS score from admission to discharge</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">850</enrollment>
  <condition>Cerebrovascular Stroke</condition>
  <condition>Cerebral Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>sCAS patients</arm_group_label>
    <description>Investigators plan to enroll 850 patients of symptomatic cerebral atherosclerotic stenosis (sCAS) for cerebral autoregulation assessment to explore the relationship between cerebral autoregulation (CA) and stroke recurrence, determine the threshold values of CA parameter for predicting stroke recurrence associated with particular stenosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cerebral autoregulation assessment</intervention_name>
    <description>Cerebral autoregulation assessment will be conducted by specialized neurovascular ultrasound doctors during 0-3 and 10-30 days after stroke onset.The recorded data will be stored for further cerebral autoregulation analysis.</description>
    <arm_group_label>sCAS patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of symptomatic cerebral atherosclerotic stenosis, were recruited&#xD;
        according to Inclusion Criteria, mostly from the First Hospital of Jilin University, and&#xD;
        partly from other hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ranging from 18 to 80, both genders&#xD;
&#xD;
          -  Unilateral internal carotid artery (ICA) or M1 segment of middle cerebral artery (MCA)&#xD;
             stenosis (rate of stenosis ranging from 50-99%)&#xD;
&#xD;
          -  Acute ischemic cerebrovascular events (TIA or ischemic stroke) within cerebral&#xD;
             stenotic artery supplying area&#xD;
&#xD;
          -  Onset of disease &lt;30 d before enrollment&#xD;
&#xD;
          -  Modified Ranking Scale (mRS) ≤1 before stroke onset&#xD;
&#xD;
          -  National Institutes of Health Stroke Scale (NIHSS) ≤20&#xD;
&#xD;
          -  Sufficient bilateral temporal bone windows for insonation of the middle cerebral&#xD;
             artery&#xD;
&#xD;
          -  Be conscious, and able to cooperate with CA assessment&#xD;
&#xD;
          -  Willing to participate and sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Vertebral artery (VA), basilar artery (BA), anterior cerebral artery (ACA), or&#xD;
             posterior cerebral artery (PCA) stenosis; Bilateral internal carotid artery (ICA) or&#xD;
             M1 segment of middle cerebral artery (MCA) stenosis(rate of stenosis ranging from&#xD;
             50-99%)&#xD;
&#xD;
          -  Patients who have received or plan to undergo intravascular interventional&#xD;
             treatment/endarterectomy&#xD;
&#xD;
          -  Other intracranial diseases, including cerebral hemorrhage (primary or secondary),&#xD;
             intracranial neoplasm, aneurysm, arteriovenous malformation, etc.&#xD;
&#xD;
          -  Evidence for embolic stroke, such as atrial fibrillation, prosthetic valve surgery,&#xD;
             and suspected endocarditis, etc.&#xD;
&#xD;
          -  Arrhythmia, anemia and hyperthyroidism which may influence the stability of cerebral&#xD;
             blood flow diagnosed by two physicians by electrocardiogram and laboratory tests.&#xD;
&#xD;
          -  Dementia, severe anxiety, depression, and other mental diseases&#xD;
&#xD;
          -  Malignant neoplasm and expected lifetime &lt;2 years&#xD;
&#xD;
          -  Enrolled in other clinical trails within 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yi Yang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Neuroscience Center, Department of Neurology, The First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yi Yang, MD, PhD</last_name>
    <phone>0086-13756661217</phone>
    <email>doctor_yangyi@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhenni Guo, MD</last_name>
    <email>zhen1ni2@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Yang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 19, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The First Hospital of Jilin University</investigator_affiliation>
    <investigator_full_name>Yi Yang</investigator_full_name>
    <investigator_title>Associated Dean of First Hospital of Jilin University</investigator_title>
  </responsible_party>
  <keyword>cerebral atherosclerotic stenosis</keyword>
  <keyword>ischemic stroke</keyword>
  <keyword>transient ischemic attack</keyword>
  <keyword>cerebral autoregulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

